Fig. 5From: Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseasesDistribution of FDA orphan drug designations within broad disease category by decade, 1983—2019Back to article page